Labcorp will deploy Roche’s cobas Mass Spec platform in its US labs, marking the first commercial rollout of this fully automated mass spectrometry system to streamline complex diagnostic testing workflows.
A 44-metabolite blood test signature identified by Mass General Brigham and Einstein researchers improved type 2 diabetes risk prediction in a study of over 23,000 participants, according to Nature Medicine.
AI, new diagnostics, and shifting care delivery models are among the clinical laboratory predictions for 2026.
The AI-powered pathology tool becomes the first AI-based drug development tool to receive FDA qualification, following earlier EMA approval.
The collaboration will provide urologists and oncologists nationwide access to AI-powered tools for non-muscle invasive bladder cancer management.
The all-in-one diagnostic platform combines hematology, biochemistry, and immunoassay testing in a single run.
The company's cell analyzer will enable the investigation of 30-plus cellular characteristics to capture key biological insights and support a planned 1,000-person immune profiling study.
Fast, patient-specific blood test results during surgery can help clinicians decide when transfusions are truly needed.Â
The qPCR-based test detects variants that increase risk of severe fluoropyrimidine chemotherapy toxicity.
The approval expands the company's automated mass spectrometry menu to 39 tests.
The exsig Mag RapidBead Pro kit features a four-step workflow that reduces extraction time to under 20 minutes.
Partnership with Certest Biotec adds respiratory and STI molecular diagnostic panels for European laboratories.
The cobas liat system delivers PCR results in 15 minutes, detecting and differentiating between three Bordetella pathogens including whooping cough.
Researchers have developed a direct urine testing approach that bypasses traditional bacterial culture requirements.